Assistant Professor of Oncology, Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA
Institute of Cancer Therapeutics University of Bradford, UK.
Associate Professor,Faculty of Pharmacy,Department Of Pharmacology and Therapeutics,Kuwait University.
Harvard Medical School Chief, Division of Translational Therapeutics, Department of Medicine, Director of Translational Therapeutics, Cancer Research Institute, United States.
Formulation Scientist at Insys Therapeutics
Senior Research Associate, Department of Therapeutic Endocrinology, Endocrinology Research Center, Moscow, Russia
Senior Scientist/Pre-Clinical Manager, Repros Therapeutics, The Woodlands, TX
Diagnostic and Therapeutic Technologies Department, School of Health Sciences - Polytechnic Institute of Bragança, Portugal
Ph.D. in Pharmaceutical Sciences, Formulation Scientist, Insys Therapeutics, University of Nebraska Medical Center, USA
Department of Clinical and Experimental Therapeutics, University of Georgia, Augusta, USA
Postdoctoral research Fellow in the Department of Neurology and Neurotherapeutics at University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Assistant Professor in the Department of Molecular Pharmacology and Therapeutics of Loyola University Chicago, USA.
Author(s): Moukobolo Kinsangou Franck Arnaud1,2 , Poaty Henriette1,3*
Author(s): Quasney, Michael W. MD University of Michigan, Ann Arbor, MI.
Author(s):
Semra SONGUT, Zehra AYDIN
Author(s): Vinay Kumar
Author(s): Lucia Kiio* , Damaris Mbui and Peter Ndangili
Author(s): US Food and Drug Administration (FDA) exercises flexibility in the requirement that new drugs provide substantial evidence of benefit under the Food, Drug and Cosmetic Act. Provisions in law and policy provide numerous exceptions to the historical scientific standard of 2 or more controlled clinical trials demonstrating statistically significant evidence of benefit.